SEARCH

SEARCH BY CITATION

References

  • 1
    Jones RN, Barry AL, Thornsberry, C. In vitro studies of meropenem. J Antimicrob Chemother 1989; 24 (suppl. A): 929.
  • 2
    Labia R, Morand A, Guionie M. β-Lactamase stability of imipenem. J Antimicrob Chemother 1986; 18 (suppl. E): 18.
  • 3
    Odete Santos-Ferreira M, Vital JO. In vitro antibacterial activity of imipenem compared with four other β-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 clinical isolates from a Portuguese hospital. J Antimicrob Chemother 1986; 18 (suppl. E): 236.
  • 4
    Moellering Jr RC, Eliopoulos GM, Sentochnil DE. The carbapenems: new broad spectrum β-lactam antibiotics. J Antimicrob Chemother 1989; 24 (suppl. A): 17.
  • 5
    Tuomanen E. Phenotypic tolerance: the search for β-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 1986; 8 (suppl. 3): 27991.
  • 6
    Ashby MJ, Neale JE, Knott SJ, Critchley IA. Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli. J Antimicrob Chemother 1994; 33: 44352.
  • 7
    Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 2837.
  • 8
    Odenholt I, Isaksson B, Nilsson L, Cars O. Postantibiotic and bactericidal effect of imipenem against Pseudomonas aeruginosa. Eur J Clin Bacteriol Infect Dis 1989; 8: 13641.
  • 9
    Okamoto O, Fukatsu H, Nakagawa S, Tanaka N. BO-2727 and its related compounds, new β-methyl carbapenems. In: Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract 898. Washington , DC : American Society for Microbiology, 1993: 284.
  • 10
    Asahi Y, Miyazaki H, Shibata K, Sanada M, Nakagawa S, Tanaka N. BO-2727, a new injectable β-methyl carbapenem: in vivo antibacterial activity. In: Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract 903. Washington , DC : American Society for Microbiology, 1993: 285.
  • 11
    Nakashima M, Uematsu T, Kosuge K, Umemura K. Phase I study of BO-2727, a new injectable β-methyl carbapenem antibiotic. In: Program and Abstracts of the Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract 906. Washington , DC : American Society for Microbiology, 1993: 285.
  • 12
    Löwdin E, Odenholt-Tornqvist I, Cars O. A new method to determine the postantibiotic effect and effects of subinhibitory antibiotic concentrations. Antimicrob Agents Chemother 1993; 37: 22005.
  • 13
    Craig WA, Gudmundsson S. The postantibiotic effect. In LorianV, ed. Antibiotics in Laboratory Medicine, 3rd edn. Baltimore , Williams & Wilkins Co., 1991: 40331.
  • 14
    Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem. J Antimicrob Chemother 1993; 31: 88192.
  • 15
    Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108:83540.
  • 16
    Cometta A, Moosmann Y, Franciolli M, Billie J, Glauser MP. Absence of correlation between increasing penicillin G (PNG) concentrations and efficacy in the treatment of streptococcal aortic valve rat endocarditis. In: Program and Abstracts of the Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA. Abstract 361. Washington , DC : American Society for Microbiology, 1988: 173.
  • 17
    Gerber AU. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides: basic considerations and experimental approach. J Drug Device 1988; 1 (suppl. 3): 1723.
  • 18
    Kirby WN. Bacteriostatic and lytic actions of penicillin on sensitive and resistant staphylococci. J Clin Invest 1945; 24: 1659.
  • 19
    Eagle H, Fleischman R, Musselman AD. Effect of schedules of administration on the therapeutic effect of penicillin. Am J Med 1950; 9: 28099.
  • 20
    Griffiths LR, Green HT. Paradoxical effect of penicillin in vivo. J Antimicrob Chemother 1985; 15: 5078.
  • 21
    George RH, Dyas A. Paradoxical effect of penicillin in vivo. J Antimicrob Chemother 1986; 17: 6845.
  • 22
    Shah PM, Junghanns W, Stille W. Dosis-Wirkungs-Beziehung der Bakterizidie bei E. coli, K. pneumoniae und Staphylococcus aureus. Dtsch Med Wochenschr 1976; 101: 3258.
  • 23
    Craig WA, Ebert S. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 257783.
  • 24
    Hobby GL, Dawson MH. Effect of growth rate of bacteria on action of penicillin. Proc Soc Exp Biol 1944; 56: 1814.
  • 25
    McDonald PJ, Craig WA, Kunin CM. Persistent effects of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135: 21723.
  • 26
    Wilson DA, Rolinson GN. The recovery period following exposure of bacteria to penicillin. Chemotherapy 1979; 25: 1422.
  • 27
    Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 28798.
  • 28
    Bustamente CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effects of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 5: 67882.
  • 29
    Gudmundsson S, Vogelman B, Craig WA. The in vivo postantibiotic effect of imipenem and other new antimicrobials. J Antimicrob Chemother 1986; 18 (suppl. E): 6773.
  • 30
    Nadler HI, Pitkin DH, Sheikh W. The postantibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother 1989; 24 (suppl. A): 22531.
  • 31
    Odenholt I, Holm SE, Cars O. Effects of benzylpenicillin on group A β-hemolytic streptococci during the postantibiotic phase in vitro. J Antimicrob Chemother 1989; 24: 14756.
  • 32
    Odenholt I, Holm SE, Cars O. Effects of supra- and sub-MIC benzylpenicillin concentrations on group A β-hemolytic streptococci during the postantibiotic phase in vivo. J Antimicrob Chemother 1990; 26: 193201.
  • 33
    Odenholt-Tornqvist I, Löwdin E, Cars O. Pharmacodynamic effects of subinhibitory concentrations of β-lactam antibiotics in vitro. Antimicrob Agents Chemother 1991; 35: 18349.
  • 34
    Odenholt-Tornqvist I, Löwdin E, Cars O. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin and amikacin. Antimicrob Agents Chemother 1992; 36: 18528.
  • 35
    Odenholt-Tornqvist I, Löwdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39: 2216.
  • 36
    Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 83147.
  • 37
    Roosendaal R, Bakker-Woundenberg IAJM, van den Berghe-van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leucopenic rats. Antimicrob Agents Chemother 1986; 30: 4038.
  • 38
    Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose—effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 28192.
  • 39
    Fantin B, Ebert S, Leggett J, Vogelman B, Craig WA. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. J Antimicrob Chemother 1990; 27: 82936.
  • 40
    Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 48390.
  • 41
    Forrest A, Nix D, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 107381.